biomarkers is pivotal for designing new treatment strategies able to reduce HGSOC-99 related mortality. In this context, the cancer stem-like cell (CSC) theory represents 100 one model to investigate OC heterogeneity. This hypothesis, supported by increased 101 evidence acquired in the last decade, proposes that, within OC tissues, a small 102 population of cells has an increased capacity for self-renewal, tumorigenesis and 103 differentiation [6] . In multiple experimental studies CSCs showed to increase potential 104 of tumorigenesis, metastasis/invasion, neoangiogenesis and chemoresistance [7, 8] and 105 have been often correlated with a poor prognosis [9] [10] [11] [12] [13] . 106
Several potential CSC markers have been identified in OC samples [14] [15] . Among 107 them, aldehyde dehydrogenase-1 (ALDH1) and CD133 are currently the best 108 characterized for ovarian CSCs. Their expression on the cell surface is associated with 109 increased tumorigenesis and self-renewal capability [16] [17] [18] . Nevertheless, the clonal 110 evolution of CSCs throughout the course of disease, from primary (pOC) to recurrent 111 (rOC) OC, has not been elucidated yet and information about the changes in CSC 112 presence within the tumor after relapse is still lacking. 113
The aim of this study was to investigate the evolution of CSC biomarkers CD133 and 114 ALDH1 expression in a large series of paired primary and recurrent HGSOCs. 115 
116

MATERIALS AND METHODS 117
Sample Collection
Clinical Data and Follow-up 157
Patients' clinical data and information on 52 patients' germline and/or somatic BRCA 158 status were retrieved from OCTIPS Consortium database [23] [24] . Platinum-159 resistance and platinum-sensitivity were defined, according to GCIG, as relapse 160 occurring before or after six months following the last platinum-based chemotherapy, 161 respectively [25] . Recurrence was defined basing on RECIST Criteria [26] . A sole 162 CA125 serum elevation was not considered relapse [27] . 163
Statistical Analysis 164
Statistical analysis was performed using SPSS version 22.0(SPSS Inc, Chicago, IL, 165 USA). To assess the difference between pOCs and rOCs in terms of biomarker 166 expression, the correlation test (Spearman coefficient, 2-tailed) and the "Wilcoxon 167 signed rank" non-parametric test for related samples were applied. Correlation of 168 CD133 and ALDH1 tumor expression with patients' clinico-pathological categorical 169 data was assessed using the Fisher's exact test. Patients' progression-free 170 interval(PFI), progression-free survival (PFS) and overall survival(OS) were 171
determined by Kaplan-Meier analysis (Log-Rank test).PFI represented the time 172
interval from the last adjuvant chemotherapy to relapse, whereas progression-free 173 survival (PFS) was the time interval between first recurrence diagnosis and tumor 174 progression. For univariate and multivariate survival analyses, the Cox regression 175 model was used. Multivariable models were performed among variables reporting a 176 p-value≤0.1 in univariate analysis. P values≤0.05 were considered statistically 177 significant. 178
179
RESULTS
180
Primary and recurrent intra-patient paired tumor samples derived from 112 HGSOC 181 patients were analyzed for CD133 and ALDH1 expression. Patients' characteristics 182 are listed in Table 1 . 183
Immunohistochemistry staining showed that ALDH1 and CD133 proteins were 184 CD133/ALDH1 co-expression in pOCs, 22(84.6%) lost this pathological 209 characteristic in relapse situation. Of the 17 patients presenting biomarker co-210 expression in rOC, 13(76.5%) showed no co-expression in pOC. Consequently, 4/112 211 patients (3.6%) showed CD133/ALDH1 co-expression in both pOC and rOC: two of 212 them were platinum-resistant and two were platinum-sensitive. 213
CSCs biomarkers and clinico-pathological factors 214
We analyzed the correlation of ALDH1 and/or CD133 tumor expression patterns in 215 pOCs with patients´ clinico-pathological characteristics. All primary CD133 + patients 216 were diagnosed at FIGO III/IV stage (p=0.006). No correlation was observed between 217 other clinico-pathological factors and ALDH1 and/or CD133 tumor 218
expression(Tab.2). 219
Survival 220 CD133 positivity in pOCs was significantly associated with poor PFI and OS 221 (Fig.5a,5b) Fig.5f ) patients with ALDH1+ and ALDH1rOC. 226
Median OS for ALDH1
+ and ALDH1 -patients was 52 and 64 months, respectively 227 (p=0.402) and median PFI-1 was 9 and 17 months, respectively (p=0.199) (Fig.5d,5e) . 228 ALDH1/CD133 co-expression in pOCs was found to significantly affect HGSOC 229 patients' outcome. A significant decrease in OS and PFI has been found in patients 230 co-expressing ALDH1/CD133 in primary tissue (46 and 9 months, respectively) 231 compared to patients without biomarker co-expression (68 and 17 months, 232 respectively) (p=0.019, Fig.5g;p=0.015,Fig.5h ). No significant difference in PFS after 233 relapse was observed between patients who reported CD133/ALDH1 co-expression or 234 no co-expression in rOC(p=0.898, Fig.5i) . 235
On multivariate analysis, the co-expression of ALDH1 and CD133 in pOC, rather 236 than the single expression of one biomarker, was identified to be an independent 237 prognostic factor for both PFI (HR:1.638;95%CI:1.033-2.598;p=0.036) and OS 238 (HR:1.707;95%CI:1.012-2.881;p=0.045) in HGSOC (Tab.3,4) . 239
Outliers' sub-analysis 240 "Outliers" were considered patients for whom the highest difference between pOC 241 and rOC could be detected in CD133+cell rate. Three patients were identified: two 242 reported a difference in CD133+cell rate of -90%(from 90% of CD133+cells at pOC 243 to 0% at rOC); the first one was a platinum-resistant patient with PFI of 2 months and 244 OS of 14 months; the second one was a platinum-sensitive patient with PFI of 7 245 months and OS of 9 months. The third patient showed a difference in CD133+cell 246 rate of +70%(from 0% of CD133+ at pOC cells to 70% in rOC) with PFI of 15 247 months (platinum-sensitive) and OS of 44 months. 248
CSC biomarker expression and BRCA status 249
In order to investigate if BRCA mutations could influence CSC biomarker expression, 250 a subgroup analysis was carried out among 52 patients, whose germline and/or 251 somatic BRCA status (assessed on pOC and rOC) was available [24] . 40.4% of tested 252 patients (21/52) had a somatic BRCA mutation in both pOCs and rOCs: 16/52(30.8%) 253
were BRCA1-mutated (mBRCA1) and 5/52(9.6%) were BRCA2-mutated 254 (mBRCA2)(Tab.5). Among BRCA-WT patients, only 1/31 patient (3.2%) showed CD133/ALDH1 co-272 expression in both pOCs and rOCs. In 3/31(9.7%) patients the co-expression was 273 evidenced in rOCs but not in pOCs. 90% of patients (9/10) reporting CD133/ALDH1 274 co-expression in pOC lost biomarker co-expression at tumor relapse. 275 Also for mBRCA1/2 patients, only 1/21(4.8%) patient showed CD133/ALDH1 co-276 expression in both pOC and rOC. Two patients (9.5%) had co-expression at recurrent 277 rather than at primary disease. The difference between BRCA-WT and mBRCA1/2 278 patients in terms of co-expression loss at rOC was not significant (4/5 vs 9/10,p=1, 279
Fisher's exact test). 280
Considering patients who were CD133+ and/or ALDH1+ at pOC, no significant 281 difference could be detected in PFI and OS among BRCA-WT vs mBRCA1/2 282 cases (Fig.8) . 283
284
DISCUSSION 285
In the Era of Precision Medicine, huge steps have been taken in the understanding of 286 HGSOC biology. In this tumor setting, the role of CSC and its clonal evolution during 287 subsequent disease relapse has been relatively unexplored. 288
This study investigated the changes in CSC biomarkers CD133 and ALDH1 289 expression in primary and recurrent HGSOCs and showed that CD133+CSCs are 290 significantly more represented in pOCs rather than rOCs, whereas no significant 291 changes in terms of ALDH1 expression levels occurred at disease relapse. Other recent meta-analysis demonstrated that also ALDH1 is a promising prognostic 301 biomarker for breast [ was an independent prognostic factor for OS. These results differ from our findings, 308 since in our population ALDH1 did not have an impact on patients' survival. 309
Nevertheless, in Liebscher's population the frequency of FIGO Stage I-II cases was 310 higher than in our population (11.5% vs 7.2%), while the number of optimally 311 cytoreduced patients was lower (66.3% vs 80.4%). 312
Silva [32] showed that the co-expression of CD133 and ALDH1 correlated with 313 significant worse PFI and OS in a small cohort of 56 ovarian cancer patients. These 314 results were in accordance with our findings in a larger HGSOC population. 315
To our knowledge, this is the first study analyzing the evolution of CSC markers in 316 the largest cohort of primary and recurrent HGSOC patients. Furthermore, the 317 subanalysis on patients with known BRCA status increases the value of the findings 318 by taking into consideration the genetic influence of BRCA status on patients' 319 survival[33-34]and provides a first evidence of the correlation between tumor-320 initiating cells and homologous recombination deficieny. Limitation of the study was 321 the lack of information regarding BRCA1/2 status on all enrolled patients. The 322 analysis on a cohort of 52 patients could not provide definitive conclusions for this 323
issue. 324
Interestingly, we observed that 84.6% of our patients' cohort reporting 325 CD133/ALDH1 co-expression in pOC lost this pathological characteristic at relapse. 326
Nevertheless, while CSC biomarker expression is significantly correlated with poor 327 prognosis, it is enigmatic why in a recurrent setting, which represents a more 328 aggressive step of the disease compared to primary disease, CSCs are less frequently 329 encountered. Theoretically, CSCs were expected to be much more frequent in rOC 330 than in the pOC. We hypothesize that the reduction in CSC biomarker expression 331 does not represent a reduction in CSC number within the tumor sample, but might be 332 the result of cellular reprogramming occurring in the CSC itself, which might lead to 333 the loss of CSC biomarker expression. Studies on this issue are still lacking. 334
This study shows that CD133 and ALDH1 as biomarkers can have influence on 335 HGSOC patients' survival and for the first time suggests that they might be caused by 336 a phenotypical change during the course of the disease similarly to non stem-like 337 cancer cells. However, the need for recurrent tumor tissue to be analyzed implied that 338 this cohort of samples might be not the most representative one for ovarian cancer 339 patients, due to the fact that most of patients had a platinum sensitive relapse, and 340 surgical approach at relapse was feasible. For this reason, general conclusion for the 341 whole recurrent ovarian cancer setting cannot currently be drawn. 342
Another limitation of the study is that these biomarkers, in particular ALDH1, are 343 
